LYRA News and Press, Lyra Therapeutics Inc. From 03/09/21

Lyra Therapeutics, Inc. (LYRA) Q4 2020 Earnings Conference Call March 09, 2021 04:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group Maria Palasis - President & Chief Executive Officer Rob Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Cori...

Lyra Therapeutics (LYRA): FY GAAP EPS of -$2.59 misses by $0.58.Cash and cash equivalents as of December 31, 2020 were $74.6 million, compared with $81.6 million as of September 30, 2020.Positive Topline Results for LANTERN Phase 2 Study of LYR-210.Robert Kern, MD, appointed Chief Medical Off...

- Positive Topline Results for LANTERN Phase 2 Study of LYR-210- - Robert Kern, MD, appointed Chief Medical Officer - - Conference call and webcast today at 4:30 p.m. ET - Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the develo...

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced the company wi...

Thought leader in the ENT treatment community brings insight from clinical practice to next stage of development for LYR-210 and pipeline Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of no...

Gainers: RCM Technologies (RCMT) +85%.Ayala Pharmaceuticals (AYLA) +60%.ESSA Pharma (EPIX) +45%.GenMark Diagnostics (GNMK) +29%.Castor Maritime (CTRM) +28%.Borqs Technologies (BRQS) +26%.SOS Limited (SOS) +25%.Lyra Therapeutics (LYRA) +25%.Inpixon (INPX) +25%.Quotient Technology (QUOT) +...

AC Immune SA (ACIU) +112% as its vaccine generates potent anti-pTau antibody response in a phase 1b/2a study.RCM Technologies, Inc. (RCMT) +92%.Sundial Growers Inc. (SNDL) +48%.MicroVision, Inc. (MVIS) +44% after long range lidar update.Monopar Therapeutics (MNPR) +41% on poten...

Lyra Therapeutics (LYRA) says that End of Phase 2 Meeting with FDA for LYR-210 is expected in mid-2021 to discuss the results from the LANTERN Phase 2 trial, and intends to initiate a Phase 3 trial at the end of 2021.The company reported results from the Phase 2 study that showed that LY...

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today provided a corporate upd...

Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...